Registry of CytoSorb Therapy in COVID-19 ICU Patients (CTC REGISTRY)

CytoSorbents

Status: Completed

Conditions: COVID-19

Treatments: Device: CytoSorb 300 mL device

Study type: Observational

Funder types: Industry

Identifiers

NCT04391920

2020-001

FDA EUA (Other Identifier)

Details and patient eligibility

About

The CTC Registry collects patient-level clinical data on CytoSorb hemoadsorption provided to COVID-19 ICU patients via integration of the CytoSorb device into ECMO, CRRT, or hemoperfusion extracorporeal circuits. The intent of the registry is to gain understanding on how CytoSorb hemoadsorption provides clinical benefit to COVID-19 ICU patients.

Enrollment: 138 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Confirmed COVID-19
2. Provision of CytoSorb therapy per Instructions for Use (IFU) of the CytoSorb device.

Exclusion criteria

1. CytoSorb therapy for diseases other than COVID-19
2. Survival unlikely within 24 hours (for prospectively enrolled patients)

Trial design

138 participants in 1 patient group

COVID-19 ICU Patients

Treatment:

Device: CytoSorb 300 mL device